Plaque Psoriasis: Clinical Trials

242 completed, 21 recruiting, 20 active not recruiting, 20 terminated. 103 Phase 3, 96 Phase 2, 53 Phase 4, 36 Phase 1, 16 Not applicable.

By phase and status

Phase	Trials	Status
Phase 3	103	Completed 78, Active not recruiting 11, Recruiting 6, Terminated 3, Unknown 2, Withdrawn 2, Not yet recruiting 1
Phase 2	96	Completed 68, Terminated 6, Active not recruiting 4, Not yet recruiting 4, Withdrawn 4, Recruiting 3, Suspended 3, Unknown 3, Enrolling by invitation 1
Phase 4	53	Completed 41, Terminated 5, Not yet recruiting 3, Unknown 2, Recruiting 1, Withdrawn 1
Phase 1	36	Completed 27, Unknown 4, Recruiting 3, Terminated 2
Not applicable	16	Unknown 7, Completed 5, Recruiting 2, Not yet recruiting 1, Terminated 1
Early Phase 1	4	Completed 2, Recruiting 1, Terminated 1

Follow Plaque Psoriasis: new trials by email Literature Review of Plaque Psoriasis trials Research Report on Plaque Psoriasis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Comparative Study on Unani Formulation Vs Active Control in Plaque Psoriasis Marham Asfedaj, Mundij wa Mushil Sawda (Unani Oral decoction), Coal tar 1% & Salicylic acid 3 % solution - Chronic Plaque Psoriasis, Plaque Psoriasis	Phase 2	Not yet recruiting	National Institute of Unani Medicine, Bengaluru	54	2027-04-01	2026-09-25
Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis IRX4204, Placebo - Psoriasis, Plaque Type Psorisis	Phase 2	Suspended	Io Therapeutics	20	2027-03-01	2026-11-12
A Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaque Psoriasis COL-5671-PRO, Placebo - Plaque Psoriasis	Phase 2	Not yet recruiting	Coultreon Biopharma	100	2026-10-31	2026-11-03
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy Plaque Psoriasis		Not yet recruiting	Novartis Pharmaceuticals	3718	2026-10-30	2026-10-20
An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis ORKA-002 - Plaque Psoriasis	Phase 2	Enrolling by invitation	Oruka Therapeutics, Inc.	160	2026-10-26	2026-11-12
Prevalence of Fibromyalgia in Patients With Plaque Psoriasis Plaque Psoriasis, Fibromyalgia		Not yet recruiting	Assiut University	110	2026-09-01	2026-08-19
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Plaque Psoriasis SHR-1139, SHR-1139 and SHR-1139 pleacebo - Plaque Psoriasis	Phase 2	Not yet recruiting	Guangdong Hengrui Pharmaceutical Co., Ltd	50	2026-08-01	2026-08-11
A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period ZP9830, Placebo - Plaque Psoriasis	Phase 1	Recruiting	Zealand Pharma	32	2026-07-22	2026-07-29
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD Plaque Psoriasis, Metabolic Dysfunction-Associated Steatotic Liver Disease		Recruiting	Novartis Pharmaceuticals	150	2026-07-08	2026-11-09
Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients Secukinumab 300mg s.c., Metformin, Placebo - Psoriasis, Plaque Psoriasis	Phase 4	Not yet recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	186	2026-06-01	2026-03-25
A Phase 3 Clinical Study of QL2106 Injection QL2106 injection, Tremfya® - Plaque Psoriasis	Phase 3	Active not recruiting	Qilu Pharmaceutical Co., Ltd.	318	2026-05-27	2026-10-19
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis ORKA-002, Placebo - Plaque Psoriasis	Phase 2	Active not recruiting	Oruka Therapeutics, Inc.	160	2026-03-19	2026-10-16
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis ORKA-001 - Plaque Psoriasis	Phase 2	Recruiting	Oruka Therapeutics, Inc.	240	2026-02-23	2026-10-23
Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia vunakizumab and recaticimab., vunakizumab and placebo - Plaque Psoriasis	Phase 4	Not yet recruiting	Xiangya Hospital of Central South University	40	2026-01-20	2026-01-28
A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis D-2570 Tablet, BMS-986165 Tablet, Placebo - Plaque Psoriasis	Phase 3	Recruiting	InventisBio Co., Ltd	477	2026-01-12	2026-04-29
A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects MC2-01 cream, MC2-01 vehicle, CAL/BDP Gel - Plaque Psoriasis	Phase 3	Completed	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	539	2025-12-30	2026-08-28
Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis ICP-332 Tablets, ICP-332 Placebo Tablets - Plaque Psoriasis	Phase 2	Recruiting	Beijing InnoCare Pharma Tech Co., Ltd.	172	2025-12-22	2025-12-31
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis Zasocitinib, Placebo - Plaque Psoriasis	Phase 3	Recruiting	Takeda	110	2025-12-04	2026-09-09
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis ORKA-001, Placebo - Plaque Psoriasis	Phase 2	Active not recruiting	Oruka Therapeutics, Inc.	160	2025-12-03	2026-11-06
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis Deucravacitinib, Placebo - Plaque Psoriasis	Phase 3	Recruiting	Bristol-Myers Squibb	366	2025-12-03	2026-10-27

Showing 20 of 349. Sign in to see all of them.

Narrower conditions

Psoriasis (81)  ·  Skin Diseases (14)  ·  Arthritis, Psoriatic (11)  ·  Plaque, Amyloid (9)  ·  Arthritis, Rheumatoid (7)  ·  Crohn Disease (6)  ·  Pruritus (6)  ·  Hidradenitis Suppurativa (5)  ·  Acne Vulgaris (3)  ·  Colitis, Ulcerative (3)  ·  Dermatitis, Atopic (3)  ·  Spondylitis, Ankylosing (3)  ·  Axial Spondyloarthritis (2)  ·  Lichen Planus (2)  ·  Lymphoma, Follicular (2)

Broader conditions

Skin and Connective Tissue Diseases (99)  ·  Skin Diseases, Papulosquamous (91)  ·  Skin Diseases (83)  ·  Pathological Conditions, Signs and Symptoms (21)  ·  Immune System Diseases (16)  ·  Musculoskeletal Diseases (14)  ·  Joint Diseases (13)  ·  Arthritis (12)  ·  Bone Diseases (11)  ·  Spinal Diseases (11)  ·  Spondylarthritis (11)  ·  Spondylarthropathies (11)  ·  Signs and Symptoms (10)  ·  Spondylitis (10)  ·  Connective Tissue Diseases (9)

Interventions

secukinumab (18)  ·  apremilast (17)  ·  Adalimumab (16)  ·  Etanercept (15)  ·  Ustekinumab (12)  ·  deucravacitinib (10)  ·  ixekizumab (10)  ·  tildrakizumab (10)  ·  calcipotriene (9)  ·  Exercise (6)  ·  betamethasone dipropionate, calcipotriol drug combination (6)  ·  Methotrexate (5)  ·  guselkumab (5)  ·  Certolizumab Pegol (4)  ·  halobetasol (4)

Sponsors

Novartis Pharmaceuticals (16)  ·  Pfizer (13)  ·  Therapeutics, Inc. (13)  ·  Amgen (12)  ·  Eli Lilly and Company (10)  ·  Janssen Research & Development, LLC (10)  ·  Almirall, S.A. (9)  ·  Sun Pharmaceutical Industries, Inc. (8)  ·  Bausch Health Americas, Inc. (7)  ·  Galderma R&D (7)  ·  Arcutis Biotherapeutics, Inc. (6)  ·  Bristol-Myers Squibb (6)  ·  Shanghai Yueyang Integrated Medicine Hospital (6)  ·  Takeda (6)  ·  Alumis Inc (5)

Countries

United States (172)  ·  Canada (87)  ·  Germany (67)  ·  Poland (52)  ·  China (48)  ·  Spain (38)  ·  Hungary (32)  ·  France (28)  ·  United Kingdom (28)  ·  Italy (23)  ·  Japan (23)  ·  Czechia (21)  ·  Australia (19)  ·  Bulgaria (18)  ·  South Korea (16)

Top investigators

David Berk, MD (6)  ·  Binu J Alexander (4)  ·  Jia Zhou (3)  ·  Robert Bissonnette, MD (3)  ·  Ronald W Gottschalk, MD (3)  ·  Syd Dromgoole, PhD (3)

Results publications

PMID 32531798, PMID 37076998, PMID 37697121, PMID 40600584, PMID 28596043, PMID 29660421, PMID 30915660, PMID 31218661, PMID 31268369, PMID 31424709, PMID 32162721, PMID 32652544, PMID 35279805, PMID 36098877, PMID 36509889, PMID 37316690, PMID 38123875, PMID 38521874, PMID 40365708, PMID 40862624, PMID 40976249, PMID 41424381, PMID 41838287, PMID 42397072, PMID 14627786, PMID 15948997, PMID 20124563, PMID 20926833, PMID 21386955, PMID 21455550, PMID 21504485, PMID 21574983, PMID 21877508, PMID 22106730, PMID 22348620, PMID 24790410, PMID 25913550, PMID 25994179, PMID 26390837, PMID 26422722, PMID 27059729, PMID 27500949, PMID 27876460, PMID 28478975, PMID 29266308, PMID 29502110, PMID 29657667, PMID 29660425, PMID 30054164, PMID 30207587

NIH funding

2023 (8), 2015 (6), 2019 (5), 2014 (3), 2016 (2), 2009 (1), 2017 (1), 2025 (1)